Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes plc (Nasdaq:ALKS) announced the opening of applications for its Alkermes Inspiration Grants program on May 1, 2023. The program aims to distribute $500,000 in total grants to nonprofit organizations addressing addiction, serious mental illness, and cancer. This marks the seventh year of the program, which evaluates proposals focused on underrepresented populations dealing with challenges such as alcohol dependence, opioid dependence, and certain cancers. Submissions will be accepted until June 1, 2023, with grant recipients selected based on defined criteria. Alkermes emphasizes its commitment to empowering communities and supporting organizations that complement medical care.
Alkermes reiterates its commitment to addressing Alcohol Use Disorder (AUD) during National Minority Health Month and Alcohol Awareness Month. The press release highlights the disproportionate impact of AUD on certain communities, underscoring the company's dedication to support individuals affected by this disorder. The emphasis is placed on the need for awareness and support as part of their ongoing efforts to combat AUD and promote health equity.
The company aims to foster a broader understanding of AUD's implications and the importance of targeted approaches in healthcare. Further details can be accessed through Alkermes' multimedia storytelling available online.
On April 19, 2023, Alkermes plc (NASDAQ: ALKS) announced a conference call and webcast scheduled for April 26, 2023, at 8:00 a.m. ET to discuss its first quarter financial results. Interested parties can access the event through Alkermes' website, with a replay available two hours post-event. Alkermes focuses on developing innovative medications in neuroscience and oncology, with products targeting alcohol and opioid dependence, schizophrenia, and bipolar I disorder. The company has a global presence with facilities in Ireland and the U.S. Investors can expect insights into the company's financial performance and future outlook during the call.
Alkermes plc (Nasdaq: ALKS) announced the opening of its Alkermes Inspiration Grants program, starting from May 1, 2023. The program, now in its seventh year, will allocate up to $500,000 in grants to support nonprofit organizations addressing issues related to addiction, serious mental illness, and cancer. CEO Richard Pops emphasized the importance of empowering nonprofits tackling complex health challenges. The grants will focus on programs that assist populations affected by alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, melanoma, or ovarian cancer. Eligible U.S. 501(c)(3) nonprofits can submit applications until June 1, 2023. For more details and application guidelines, visit Alkermes Inspiration Grants.
Alkermes plc (Nasdaq: ALKS) has submitted a confidential draft Form 10 registration statement to the U.S. Securities and Exchange Commission, marking a significant step in its planned separation of the oncology business into a publicly traded entity, Oncology Co. This separation, expected to be completed in the second half of 2023, aims to unlock shareholder value by creating focused operational structures for each business. The Board of Directors approved the split to enhance the profitability of its neuroscience segment while the oncology branch will continue developing cancer therapies, including nemvaleukin alfa. Alkermes has retained Morgan Stanley and BofA Securities for financial advice regarding this initiative, emphasizing its commitment to advancing its strategic focus.
Alkermes has been recognized in Ragan Communications and PR Daily's 2023 list of Top Places to Work. This accolade highlights the company's commitment to creating a positive work environment and employee satisfaction.
The announcement underscores Alkermes' focus on workplace culture, which may enhance its reputation and attract talent. For those interested in joining the team, job opportunities are available on their careers page.
Alkermes plc (Nasdaq: ALKS) announced the publication of the ENLIGHTEN-Early study results for LYBALVI (olanzapine and samidorphan) in the Journal of Clinical Psychiatry. The phase 3 trial focused on body weight effects in young adults (ages 16-39) with schizophrenia or bipolar I disorder. LYBALVI demonstrated a statistically significant reduction in weight gain compared to olanzapine, with mean weight changes at Week 12 being 4.91% for LYBALVI versus 6.77% for olanzapine (p=0.012). The safety profile was consistent with prior studies. The findings contribute to the understanding of LYBALVI as a treatment option for patients early in their illness.
Alkermes hosted an enlightening discussion featuring Dr. Kevin M. Simon, Boston's Chief Behavioral Health Officer, addressing implicit bias and mental health stigma in minority communities. Dr. Simon highlighted the mental health challenges faced by Dr. Martin Luther King Jr. and emphasized the importance of allyship in promoting diversity and inclusion. Alkermes continues to focus on ending the stigma surrounding mental health issues, aligning with its commitment to innovation in neuroscience and oncology.
With a global presence, Alkermes develops medicines for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, alongside an evolving pipeline for neurodegenerative disorders and cancer.
On March 15, 2023, Alkermes plc (NASDAQ: ALKS) announced its participation in a fireside chat at the Stifel 2023 CNS Days. The event will take place on March 29, 2023, at 9:00 a.m. ET (2:00 p.m. BST). The live webcast can be accessed on the Investors tab of Alkermes' website and will be available for 14 days post-event. Alkermes is a global biopharmaceutical company focused on neuroscience and oncology, offering products for alcohol and opioid dependence, schizophrenia, and bipolar I disorder. For more details, visit www.alkermes.com.
Summary not available.